Home » Healthcare » India Human Insulin Market

India Human Insulin Market

India Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers); By Geography (Northern, Western, Southern, Eastern) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
India Human Insulin Market Size 2024	USD 604.52 million
India Human Insulin Market, CAGR	6.53%
India Human Insulin Market Size 2032	USD 1,069.26 million

Market Overview

India Human Insulin market size was valued at USD 604.52 million in 2023 and is anticipated to reach USD 1,069.26 million by 2032, at a CAGR of 6.53% during the forecast period (2023-2032).

The India Human Insulin market is driven by the rising prevalence of diabetes, with an increasing number of people being diagnosed each year. Factors such as an aging population, urbanization, and changing dietary habits contribute to this growth. The growing awareness of diabetes management and the importance of insulin therapy further boosts market demand. Additionally, advancements in insulin formulations, such as rapid-acting and long-acting insulin, are enhancing treatment options, making them more accessible and effective. Government initiatives to improve healthcare access and affordability, along with the expansion of healthcare infrastructure, also support market expansion. Trends such as the shift towards biosimilar insulin, which offers a cost-effective alternative to traditional insulin products, are gaining traction. Furthermore, innovations in insulin delivery systems, including insulin pens and pumps, are improving patient convenience and compliance, thereby driving market growth in India.

Geographically, the India Human Insulin market is expanding across all regions, with varying levels of growth driven by factors like urbanization, healthcare infrastructure, and diabetes prevalence. The Northern and Western regions, particularly cities like Delhi, Mumbai, and Pune, dominate the market due to well-established healthcare systems and higher awareness of diabetes management. The Southern region, with major hubs like Bangalore and Chennai, is also seeing significant growth, spurred by increasing healthcare accessibility and growing diabetic populations. The Eastern region, though lagging behind, is gradually catching up as urbanization accelerates and healthcare improves. Key players in the Indian human insulin market include global giants such as Novo Nordisk, Eli Lilly, and Pfizer, along with local pharmaceutical companies like Biocon, Wockhardt, and Lupin. These companies play a crucial role in offering a wide range of insulin products, including both branded and biosimilars, to cater to India’s diverse diabetic population.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The India Human Insulin market was valued at USD 604.52 million in 2023 and is expected to reach USD 1,069.26 million by 2032, growing at a CAGR of 6.53% from 2023 to 2032.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Increasing diabetes prevalence due to urbanization, sedentary lifestyles, and aging population is a major market driver.

Advancements in insulin delivery devices, such as insulin pens and pumps, are contributing to improved patient convenience and adherence.
The growing adoption of biosimilar insulin products offers cost-effective alternatives to branded insulin therapies.
Competition is intense, with key players like Novo Nordisk, Eli Lilly, Biocon, and Lupin leading the market.
Regulatory challenges, including complex approval processes for new insulin products, are a significant market restraint.
Regional variations in diabetes prevalence and healthcare infrastructure create diverse growth opportunities across Northern, Southern, Western, and Eastern India.

Report Scope

This report segments the India Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

One of the primary drivers of the India Human Insulin market is the growing prevalence of diabetes in the country. For instance, according to the International Diabetes Federation (IDF), India is home to the second-largest diabetic population globally, with millions of new diagnoses every year. The increase in diabetes cases is largely attributed to factors such as an aging population, urbanization, sedentary lifestyles, and unhealthy dietary habits. The rise in obesity rates, coupled with reduced physical activity, has led to a higher incidence of type 2 diabetes, further driving demand for insulin products. As more individuals seek effective diabetes management, the need for human insulin therapy is expected to continue growing, creating a substantial market opportunity.

Government Initiatives and Healthcare Access

Government initiatives aimed at improving healthcare access and affordability have played a significant role in the growth of the human insulin market in India. For instance, the National Pharmaceutical Pricing Authority (NPPA) regulates insulin prices under the Drug Price Control Order (DPCO) to prevent overpricing by pharmaceutical companies. The government’s focus on increasing healthcare funding, particularly for diabetes treatment, is helping to make insulin more accessible to a wider population. Public health campaigns designed to raise awareness about diabetes prevention and management also contribute to the market’s expansion. Additionally, the implementation of the Pradhan Mantri Jan Arogya Yojana (PMJAY), a government health insurance scheme, has increased access to essential medicines, including insulin, for millions of low-income families. As the Indian government continues to prioritize healthcare for its citizens, the demand for human insulin is expected to rise, benefiting both patients and manufacturers.

Advancements in Insulin Formulations and Delivery Methods

Technological advancements in insulin formulations and delivery methods have significantly contributed to the growth of the human insulin market in India. Modern insulin formulations, including rapid-acting, long-acting, and premixed insulins, offer improved flexibility and better glycemic control for diabetic patients. These advancements provide patients with more options to manage their diabetes based on their lifestyle and medical needs. Furthermore, innovations in insulin delivery systems, such as insulin pens, pumps, and smart devices, have made insulin administration more convenient, reducing patient discomfort and improving adherence to treatment regimens. These improvements in insulin products enhance the effectiveness of diabetes management and are expected to continue driving market growth.

Growing Adoption of Biosimilar Insulin

The increasing adoption of biosimilar insulin in India is another significant driver of the market. Biosimilars are biologic products that are highly similar to already approved reference insulin products but are more affordable, making them an attractive option for cost-conscious patients. The shift towards biosimilars has been further accelerated by government regulations aimed at promoting the availability of affordable medicines. Biosimilars offer a competitive alternative to patented insulin products, making them more accessible to a larger segment of the population. This trend is helping to address the high cost of diabetes treatment in India and is expected to expand the market for human insulin, particularly in lower-income groups. As more biosimilar products gain approval and acceptance, the Indian human insulin market is poised for continued growth.

Market Trends

Surge in Diabetes Prevalence

India’s escalating diabetes burden is a primary driver of the human insulin market. For instance, India has the second-largest diabetic population globally, with over 74 million people diagnosed with diabetes in 2021. Factors such as urbanization, sedentary lifestyles, and poor dietary habits contribute to this surge. The increasing number of diabetes cases necessitates effective management solutions, thereby propelling the demand for insulin therapies. Government initiatives like the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) aim to address this growing health concern, further boosting the insulin market.

Advancements in Insulin Delivery Devices

Technological innovations in insulin delivery systems are transforming diabetes management in India. For instance, the India Insulin Drug and Delivery Device Market Report highlights the increasing adoption of insulin pens, pumps, and smart devices. These devices offer precise dosing, portability, and user-friendly features, making insulin administration more manageable for patients. The growing preference for home care settings, driven by the COVID-19 pandemic, has further accelerated the demand for these advanced delivery systems.

Emergence of Biosimilar Insulin

The introduction of biosimilar insulin products is reshaping the Indian insulin market by providing cost-effective alternatives to branded insulin therapies. Indian pharmaceutical companies are developing biosimilars to cater to the price-sensitive population, thereby increasing insulin accessibility. Government policies supporting biosimilar development and approval processes have facilitated their entry into the market. This trend is expected to continue, offering patients more affordable treatment options and expanding the insulin market.

Integration of Artificial Intelligence in Diabetes Management

The integration of artificial intelligence (AI) in diabetes care is an emerging trend in India. AI-powered tools and applications are being developed to assist in monitoring blood glucose levels, predicting insulin needs, and providing personalized treatment recommendations. These innovations aim to improve treatment outcomes and patient quality of life. The increasing availability of smartphones and internet connectivity in India supports the adoption of AI-based solutions, indicating a promising future for technology-driven diabetes management.

Market Challenges Analysis

High Cost of Insulin and Affordability Issues

One of the significant challenges facing the India Human Insulin market is the high cost of insulin, particularly branded products, which remains a barrier for many diabetic patients, especially in low-income and rural areas. For instance, the National Pharmaceutical Pricing Authority (NPPA) regulates insulin prices under the Drug Price Control Order (DPCO) to prevent overpricing by pharmaceutical companies. Despite government initiatives to improve healthcare access, the affordability of insulin is still a major issue for a large section of the population. Although biosimilar insulin offers a more affordable alternative, the cost of even these products can be prohibitive for some patients. The lack of universal health insurance coverage for all citizens and the dependence on out-of-pocket expenses for a majority of the population exacerbates this challenge. Ensuring affordable access to insulin for all economic segments remains a key hurdle in the widespread management of diabetes in India.

Regulatory and Supply Chain Challenges

The regulatory environment surrounding the production and approval of insulin in India poses another challenge to market growth. While the Indian government has streamlined approval processes for biosimilars, the regulatory hurdles for introducing new insulin formulations and maintaining quality standards can be complex and time-consuming. Additionally, issues within the supply chain, such as inconsistent cold chain logistics for storing insulin, can impact the availability and efficacy of insulin products, especially in rural and remote areas. These supply chain disruptions often lead to insulin shortages or delays, affecting patient access to treatment. Addressing these regulatory and logistical challenges will be crucial to ensuring that insulin products are consistently available and accessible to the growing diabetic population in India.

Market Opportunities

The India Human Insulin market presents significant opportunities due to the growing burden of diabetes and the increasing need for effective diabetes management solutions. With diabetes rates rising steadily, driven by lifestyle changes, urbanization, and an aging population, there is a growing demand for insulin products. This creates a substantial market opportunity for manufacturers to cater to a broad range of diabetic patients. Additionally, the expansion of healthcare infrastructure and the government’s focus on improving access to healthcare, including the introduction of health insurance schemes like PMJAY, further enhances the accessibility of insulin to a larger segment of the population. This enables market players to reach untapped rural and semi-urban regions, where the prevalence of diabetes is rising but insulin access remains limited.

Furthermore, the increasing adoption of biosimilar insulin products offers considerable market potential. As biosimilars are more affordable compared to branded insulin, they provide an opportunity to reach price-sensitive populations while maintaining high therapeutic efficacy. The Indian government’s favorable policies regarding biosimilar development and approval processes are expected to drive the market’s expansion in this segment. Additionally, the growing trend of home care and advancements in insulin delivery devices, such as insulin pens and smart pumps, present opportunities for companies to innovate and offer more convenient, patient-friendly products. The rise in digital health solutions, including AI-powered tools for diabetes management, further provides opportunities for companies to explore new avenues of growth in the Indian market. These factors position India as a key market for human insulin, offering promising opportunities for both local and international players.

Market Segmentation Analysis:

By Device:

In the India Human Insulin market, the device segment is categorized into pens, syringes, and other insulin delivery systems. Insulin pens hold the largest market share due to their convenience, precision, and ease of use. These pens are designed to be portable and user-friendly, with adjustable dosage settings, making them increasingly popular among diabetic patients. They are preferred for their ability to provide accurate dosing and minimize pain during injection, contributing to higher patient adherence to prescribed regimens. Syringes, although still widely used, have seen a decline in preference in recent years, mainly due to their less convenient and more time-consuming nature. However, syringes remain an essential delivery method, particularly in rural areas with limited access to advanced healthcare devices. Additionally, other delivery systems, such as insulin pumps and continuous glucose monitors, are emerging in the market. These devices offer continuous insulin infusion and better glucose control, especially in patients with more complex diabetes management needs. The adoption of advanced delivery systems is expected to grow as the market shifts towards more personalized and effective diabetes management solutions.

By Indication:

The India Human Insulin market is also segmented based on the indication, including Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 2 diabetes represents the largest segment, primarily due to the increasing prevalence of lifestyle-related risk factors such as poor diet, obesity, and a sedentary lifestyle. The rising number of Type 2 diabetes cases in India is driving substantial demand for insulin products. Type 1 diabetes, although less common, remains a key segment as insulin is crucial for managing this autoimmune condition. The growing awareness and early diagnosis of Type 1 diabetes are further contributing to market growth. Gestational diabetes, which affects pregnant women, is another important segment, though smaller in comparison to the other two. As awareness around gestational diabetes increases and more women are diagnosed, the demand for insulin therapies tailored for pregnant women is expected to rise.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Northern
Western
Southern
Eastern

Regional Analysis

Northern Region

The Northern region of India holds a significant share of the human insulin market, accounting for approximately 30% of the total market. This region’s large share is driven by the high prevalence of diabetes, particularly in states like Delhi, Punjab, Haryana, and Uttar Pradesh. Urbanization, sedentary lifestyles, and dietary changes are major contributing factors to the rising number of diabetic patients in the North. Moreover, the region has a well-established healthcare infrastructure with several private and public hospitals offering insulin therapy, which supports market growth. The increasing awareness of diabetes management and the availability of advanced insulin delivery systems such as insulin pens and pumps are also contributing to the expansion of the insulin market in Northern India.

Western Region

The Western region of India, including states like Maharashtra, Gujarat, Rajasthan, and Madhya Pradesh, holds a market share of approximately 25%. The rise in Type 2 diabetes cases, fueled by factors such as high urbanization rates, changing diets, and increasing obesity levels, is a key driver of insulin demand in this region. Major urban centers like Mumbai, Pune, and Ahmedabad have a well-developed healthcare system, which ensures widespread availability of insulin products. Furthermore, Western India’s pharmaceutical industry, with a strong presence of both international and local manufacturers, plays a vital role in meeting the region’s demand for insulin, including biosimilars. This, coupled with the growing preference for home-based diabetes care, strengthens the region’s market position.

Southern Region

The Southern region, comprising states like Tamil Nadu, Karnataka, Andhra Pradesh, Telangana, and Kerala, holds a 20% share of the India Human Insulin market. The high incidence of diabetes in these states is largely due to dietary habits, increasing stress levels, and urbanization. Cities such as Bangalore, Chennai, and Hyderabad are major healthcare hubs where advanced diabetes treatments, including insulin therapy, are readily available. The rise of healthcare awareness in this region, along with increasing government health programs, has led to a steady increase in insulin demand. Additionally, with the expansion of health insurance coverage, more people in the Southern region are able to afford insulin therapies, further driving market growth.

Eastern Region

The Eastern region of India, which includes states like West Bengal, Odisha, Bihar, and Jharkhand, currently holds the smallest market share of around 15%. While diabetes is on the rise in Eastern India due to factors such as changing dietary patterns and growing obesity rates, the region lags behind in terms of healthcare infrastructure and access to insulin. However, with increasing urbanization and the gradual improvement of healthcare facilities, the insulin market in Eastern India is poised for growth. Awareness campaigns and government health schemes in these states are expected to boost the adoption of insulin products. As healthcare access improves, the region’s share in the overall market is likely to increase over time.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company
Eris Lifesciences

Competitive Analysis

The competitive landscape of the India Human Insulin market is dominated by both global and local players, each contributing to the market’s growth through innovation and strategic market positioning. Leading international companies such as Novo Nordisk, Eli Lilly, Pfizer, and MannKind Corporation hold a significant share, offering a range of insulin products including both branded and biosimilar insulin. Global players lead the market with their broad portfolio of insulin products, including both branded and biosimilar insulin, and focus on advanced insulin delivery systems like pens, pumps, and smart devices. Their strong presence is supported by extensive research and development, ensuring continuous improvements in insulin formulations and patient-centric solutions. Local companies have gained considerable traction by offering more affordable insulin alternatives, especially biosimilars, catering to the price-sensitive segment of the market. These players often leverage cost-effective manufacturing practices to meet the demand for insulin products in rural and semi-urban regions, where accessibility and affordability remain key challenges. The competition also extends to the development of patient-friendly delivery devices, as well as the introduction of digital health solutions to improve diabetes management. Overall, the market is highly competitive, with players focusing on product innovation, strategic pricing, and strong distribution networks to maintain their market positions and meet the diverse needs of India’s diabetic population.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The India Human Insulin market exhibits moderate concentration, with a mix of global and local players dominating the landscape. A few multinational companies hold a substantial market share due to their extensive product portfolios, which include both branded and biosimilar insulin options. These companies benefit from strong research and development capabilities, offering advanced insulin formulations and delivery systems. However, local players have gained significant traction by providing cost-effective alternatives, particularly in biosimilars, making insulin more accessible to the large, price-sensitive diabetic population in India. The market is characterized by a growing focus on patient-centric solutions, with increasing adoption of insulin pens, pumps, and other user-friendly delivery devices. Moreover, the rise in government initiatives and insurance coverage is making insulin more accessible to a broader demographic. Despite the competition, the market remains dynamic, with ongoing innovation in both insulin products and delivery systems driving the growth of the sector.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for human insulin in India is expected to continue growing due to the increasing prevalence of diabetes.
The market will see a significant shift towards biosimilar insulin products, driven by their affordability.
Advances in insulin delivery systems, such as insulin pens and pumps, will lead to greater patient convenience and improved adherence.
There will be a growing focus on digital health solutions, including AI-powered tools for personalized diabetes management.
The expansion of healthcare insurance coverage will make insulin products more accessible to a larger population.
Government initiatives and healthcare policies will play a pivotal role in improving access to insulin, especially in rural areas.
The increasing adoption of home-based diabetes management will further boost the demand for insulin products.
Regional disparities in healthcare infrastructure will create unique growth opportunities in underserved areas.
Local manufacturers will continue to expand their presence with cost-effective insulin options to cater to price-sensitive segments.
As healthcare awareness improves, more people will seek timely insulin treatment, driving market expansion.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. India Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by India 32

5.1.1. India Human Insulin Market Import Volume/Revenue, By India, 2018 – 2023 32

5.2. Export Analysis by India 33

5.2.1. India Human Insulin Market Export Volume/Revenue, By India, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by India 34

6.1.1. India Human Insulin Market Demand Volume/Revenue, By India, 2018 – 2023 34

6.2. Supply Analysis by India 35

6.2.1. India Human Insulin Market Supply Volume/Revenue, By India, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by India 36

7.1.1. India Human Insulin Market Production Volume/Revenue, By India, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. India Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. India Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. India Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. India Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. India Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. India Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. India Human Insulin Market Company Volume Market Share, 2023 43

11.3. India Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

India Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – INDIA ANALYSIS 92

18.1. Type 92

18.1.1. India Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. India Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. India Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. India Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. India Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. India Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. India Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. India Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. India Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. India Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Eris Lifesciences 99

19.1.14. Company 10 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. India Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for India Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for India Human Insulin Market 30

FIG NO. 4. India Human Insulin Market Import Volume/Revenue, By India, 2018 – 2023 32

FIG NO. 5. India Human Insulin Market Export Volume/Revenue, By India, 2018 – 2023 33

FIG NO. 6. India Human Insulin Market Demand Volume/Revenue, By India, 2018 – 2023 34

FIG NO. 7. India Human Insulin Market Supply Volume/Revenue, By India, 2018 – 2023 35

FIG NO. 8. India Human Insulin Market Production Volume/Revenue, By India, 2018 – 2023 36

FIG NO. 9. India Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. India Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. India Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. India Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. India Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. India Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. India Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. India Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. India Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. India Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. India Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. India Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. India Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. India Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. India Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. India Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. India Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. India Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. India Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. India Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. India Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. India Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. India Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. India Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : India Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : India Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : India Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : India Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : India Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : India Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : India Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : India Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : India Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : India Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : India Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : India Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the India Human Insulin?

The India Human Insulin market was valued at USD 604.52 million in 2023 and is projected to reach USD 1,069.26 million by 2032.

What factors are driving the growth of the India Human Insulin?

Rising diabetes prevalence, urbanization, biosimilar adoption, government healthcare initiatives, and advancements in insulin delivery devices are key growth drivers.

What are some challenges faced by the India Human Insulin?

Challenges include high insulin costs, regulatory complexities, limited rural access, and cold chain supply disruptions.

Who are the major players in the India Human Insulin?

Major players include Novo Nordisk, Eli Lilly, Biocon, Pfizer, Wockhardt, Lupin, MannKind, Tonghua Dongbao, and Eris Lifesciences.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –